Rick Simpson Oil (RSO) in Ouachita County, Arkansas: The Complete Guide by OilWell Cannabis

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker — a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For folks here in Ouachita County who’ve watched loved ones struggle when doctors run out of options, this story hits close to home. We’ve got neighbors in Camden, Bearden, and Stephens who know exactly what it feels like when the medical system says there’s nothing more they can do.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused. We’ve heard similar stories from veterans returning to Ouachita County from service, dealing with TBI symptoms and being handed prescriptions that don’t work or create new problems.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials. This 1974 study is still referenced in cancer research circles, and while Ouachita County residents dealing with a cancer diagnosis at the Ouachita County Medical Center or seeking treatment at larger facilities in Little Rock or Shreveport may encounter this history, it’s crucial to understand that mouse studies don’t equal human cures.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed. We share this story because we know cancer patients throughout Ouachita County — from the rural communities around Chidester to families dealing with melanoma diagnoses — are searching for hope. But hope must be grounded in honesty about what the evidence actually shows.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others. This free-distribution model resonates with Ouachita County’s community values — we take care of our neighbors here. When someone in our community is struggling with chronic pain from working on the timber farms or dealing with arthritis from years of hard labor, we understand the instinct to help without asking for payment.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational — for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine. This documentary is likely how many folks in Ouachita County first heard about RSO, perhaps through online forums or word-of-mouth from other patients at the VA clinics in El Dorado or Hot Springs.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad. This history of conflict with authorities is something many in Ouachita County understand, especially those who’ve had family members caught up in Arkansas’s cannabis criminalization before medical marijuana became legal in 2016.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil — particularly high-THC oil made according to his specific method — could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption. Folks in Ouachita County know what it’s like to feel ignored by institutions — whether it’s the timber industry closing mills or pharmaceutical companies pushing opioids through local pharmacies. Simpson’s distrust resonates here.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. For Ouachita County residents who’ve watched their communities struggle with institutional abandonment, this perspective may feel familiar.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it. For anyone in Ouachita County considering this protocol, it’s essential to understand the full context before making decisions about treatment.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC. For Ouachita County residents who may need to work at the Georgia-Pacific mill in Crossett or drive the timber roads, this initial dosing would mean significant impairment risk.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period — roughly four to five weeks in — the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method — oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method — topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary — inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect. For Ouachita County residents who work in agriculture, construction, or manufacturing, this would mean weeks off work or impaired operation of heavy equipment.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol — dietary advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition. The Ouachita County Medical Center and the cancer treatment centers in Little Rock have no data supporting this protocol.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day. That’s a massive difference that Ouachita County residents need to understand before considering such a protocol.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the research literature and are not theoretical.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself. For Ouachita County residents facing cancer diagnoses, this is a critical safety consideration.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization — the starting material varied by availability and growing season. For Ouachita County residents trying to evaluate local products, this variability is a major concern.

Extraction solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue for anyone in Ouachita County considering DIY extraction.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes — now a dark, cannabinoid-rich liquid — were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

This process is still replicated by DIY makers throughout Arkansas, but it carries significant safety risks that modern production methods have eliminated.

Appearance and physical characteristics

Traditional RSO was an extremely dark — nearly black — thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is very difficult to verify without lab testing — leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer — including terminal cases — and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document. For Ouachita County residents searching “does RSO cure cancer” or “cannabis oil for cancer,” this is the most critical section to read carefully.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial — he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products. For Ouachita County residents trying to decide between products they might find at Arkansas dispensaries or online, this comparison is essential.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is very difficult to verify without analytical chemistry equipment — leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the research literature, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius — was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material — including THCa, CBDa, CBGa, and others — were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage — because THCa can convert to THC under heating or over time.

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes — including myrcene, limonene, and pinene — having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the research section below. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing — it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The research section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature when human data are sparse. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations — that work would require its own development process and should incorporate the safety considerations documented throughout this document.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts — vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach.

Bentley’s story — the foundation

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD — through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care that now reaches Ouachita County.

Colin’s personal health journey

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat that is notoriously difficult and dangerous — using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

From personal healing to professional formulation

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs. For Ouachita County residents dealing with these conditions — perhaps veterans at the VA clinic in El Dorado, or residents managing chronic digestive issues — this medical professional usage provides significant credibility.

ABC13 media recognition

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This philosophy of radical honesty over hype is exactly what Ouachita County residents deserve — straight talk, not promises we can’t keep.

Current operations and credibility

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced — they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally. For Ouachita County residents who don’t qualify for Arkansas’s restrictive medical marijuana program, this is a game-changer.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric. This means you can use our RSO during the day for inflammation relief without impairment, then convert it for nighttime use when you need stronger effects.

3. Open-source formulas. OilWell publishes their complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe. For Ouachita County residents on fixed incomes, this transparency matters.

4. Evidence-informed, not evidence-overstating. The research section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design and is what allows us to ship to Ouachita County, Arkansas legally.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Arkansas.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to Ouachita County, Arkansas and other jurisdictions with compatible hemp laws.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Arkansas state law regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. Arkansas law allows hemp-derived products with less than 0.3% delta-9 THC, and our product meets this standard at the point of sale.

Open-source formulas — why OilWell publishes everything

OilWell publishes their complete RSO formulas publicly — every cannabinoid, every milligram amount, every percentage — in documents like this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford OilWell’s products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the product sections are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO — it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner in Ouachita County or anywhere else facing a similar crisis could make it themselves:

CBD golden paste recipe for pets — the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment. For Ouachita County residents who work at the paper mill, drive trucks through the timberlands, or need to stay sharp for their families, this is the option that makes RSO practical for daily life.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3 — Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section above.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For Ouachita County’s veteran community, this product has particular relevance.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations — OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Both products are available for delivery to Ouachita County, Arkansas.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison — OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other products Ouachita County residents might encounter. These comparisons are based on publicly available specifications.

OilWell RSO vs. Arkansas medical marijuana RSO (dispensary products)

Dimension	Arkansas dispensary RSO	OilWell RSO
Cannabinoid profile	Typically THC-only or THC-dominant	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	Usually minimal or none	3,000 mg
CBN content	Usually minimal or none	750 mg
CBC content	Usually minimal or none	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	Arkansas medical marijuana card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, severe arthritis, glaucoma, etc.	None required
Delivery	Must travel to dispensary (closest in Hot Springs or Little Rock)	Ships directly to Ouachita County
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO products

Dimension	Typical hemp CBD RSO (10-30 mL, 1,000-3,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000-3,000 mg	16,590 mg
CBD content	900-2,500 mg	4,500 mg
CBG content	Usually minimal	3,000 mg
CBN content	Usually minimal	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Price	$40-80	$129.99

OilWell RSO vs. traditional illegal RSO — Refer to the Traditional RSO vs. modern formulated RSO table in the Rick Simpson section for the complete eleven-dimension comparison.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited below and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. For Ouachita County residents, this means consulting with your physician at the Ouachita County Medical Center or your primary care provider before starting any new supplement regimen.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility

OilWell operates the only same-day RSO delivery system in Houston. For Ouachita County residents, we offer nationwide shipping that delivers directly to your doorstep in Camden, Bearden, Stephens, or anywhere in the county.

Shipping to Ouachita County, Arkansas

• All orders ship via USPS Priority Mail (2-3 business days) or FedEx/UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available
• Full documentation and COAs included for Arkansas compliance

The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to Arkansas.

International customers: We ship worldwide. The same legal framework that allows us to ship to Ouachita County allows us to ship to many countries. Customers accept all customs and legal responsibility.

How the OilWell formulas connect to the evidence

Every cannabinoid in OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the research section of this document. Every terpene in OilWell’s formula — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context — the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

OilWell’s position — as stated by Colin Valencia in 2019 — is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand — it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as the company continues to grow, the focus remains on maintaining the same level of integrity, creativity, and commitment that has defined it from the day Bentley got up, walked across the room, and brought his ball to play.

GENERAL KNOWLEDGE

The following research summaries provide the evidence foundation for every claim made about OilWell’s RSO formulas. For Ouachita County residents who value making informed decisions based on actual science rather than marketing hype, this section is essential reading.

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Cannabinoids

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient.
• What is best supported: purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety research: a 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited.
• Pain research: a 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence.
• Sleep research: a 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures.
• Safety and interaction concerns: a 2023 systematic review found a real signal for liver enzyme elevation and possible drug-induced liver injury, which is especially relevant for concentrated oral products and polypharmacy settings.

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG appears pharmacologically distinct from both THC and CBD, with interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling.
• Potential research areas: possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses.
• Bottom line: CBG is a promising minor cannabinoid with limited clinical validation.

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: a 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9 THC.
• Public-health literature: a 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies and public-health concerns rather than strong modern human trials.
• Bottom line: delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity and incomplete human safety characterization.

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material.
• Psychoactivity: THCa itself does not produce psychoactive effects, but only holds if the molecule stays in its acidic form.
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities.
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage.

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden.
• What is institutionally best supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy nausea, HIV/AIDS appetite, and some MS/pain outcomes.
• Pain evidence: a 2022 systematic review found that high-THC products may provide short-term pain benefit but increase dizziness, sedation, and discontinuation.
• Pharmacokinetics: inhaled THC produces effects within seconds to minutes; oral THC has later onset and longer duration.
• Mental-health risk: a 2025 systematic review found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder.
• Broader safety: anxiety or panic at high doses, tachycardia, dependency potential, pregnancy concerns, and vape-related lung-injury concerns.

CBN

• Evidence profile: weak human evidence; marketing has moved ahead of the data.
• What it is often marketed for: sleep and sedation, but clinical support is far thinner than the market suggests.
• Best direct review: a 2021 narrative review screened 99 human-study abstracts and found no clinical trials using validated sleep questionnaires that could substantiate strong sleep-promoting claims.
• Broader sleep literature: the 2024 updated review concluded that overall cannabinoid sleep research still does not match the scale of real-world use.
• Bottom line: CBN is one of the clearest examples where cultural reputation is stronger than the current clinical evidence base.

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical.
• Pharmacology: the 2024 focused review on CBC argues it has distinct pharmacodynamics and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting.
• What the older literature shows: anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity.
• Safety caveat: the 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: largely review and preclinical.
• Potential activity: antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory.
• Safety note: limonene oxidation products are clinically relevant contact allergens.
• Bottom line: limonene is biologically active, but cannabis-specific therapeutic claims should stay conservative.

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence.
• Research summary: anxiolytic, antioxidant, anti-inflammatory, and analgesic properties described, but human studies are lacking.
• Interpretation caution: myrcene is often invoked as a proven sedative, but that claim exceeds the human evidence.
• Bottom line: myrcene is plausible but compound-specific clinical claims remain far ahead of definitive proof.

Caryophyllene

• Evidence profile: among the most mechanistically interesting because of direct CB2 receptor agonism.
• Why it stands out: a 2021 review describes beta-caryophyllene as a selective CB2 receptor agonist, unusual for a terpene.
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective.
• Bottom line: beta-caryophyllene is the strongest candidate for a terpene with cannabinoid-system significance, but still not clinically proven for common claims.

Pinene

• Evidence profile: promising preclinical literature, weak human confirmation.
• Brain-health framing: the 2021 review found antioxidant, anti-inflammatory, and neuroprotective signals.
• Interpretation caution: claims that pinene reliably improves memory or counterbalances THC cognition effects remain hypotheses.
• Bottom line: pinene deserves attention, but strong cognition claims should be presented as exploratory.

Linalool

• Evidence profile: substantial preclinical interest, limited direct clinical confirmation.
• Research summary: repeatedly discussed in relation to stress, mood, and brain-health pharmacology.
• Safety note: oxidized linalool hydroperoxides are recognized allergens.
• Bottom line: linalool is scientifically credible, but current evidence supports cautious phrasing.

Humulene

• Evidence profile: translationally interesting, but still early.
• Scoping-review findings: a 2024 review found broad preclinical evidence for anti-inflammatory effects and possible cannabimimetic properties.
• Interpretation caution: findings are valuable for hypothesis generation, not consistent human efficacy.
• Bottom line: humulene is an interesting research target, but far from clinically settled.

Terpinolene

• Evidence profile: one of the least clinically characterized terpenes.
• Systematic-review findings: the 2021 review screened 2,449 records and concluded the evidence base is dominated by in silico, in vitro, and animal studies.
• Bottom line: terpinolene is biologically interesting, but especially underdeveloped clinically.

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC support the most detailed statements; the rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation.
• For THCa, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids.

Practical takeaways for Ouachita County residents

1. CBD and delta-9 THC have the strongest human evidence in these formulas
2. Delta-8 THC is not a trivial ingredient; it’s psychoactive with less robust safety data than delta-9 THC
3. THCa changes with processing and should not be interpreted the same way in raw vs. heated formats
4. CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC
5. Terpene claims should be careful and conservative — they’re biologically plausible but not yet clinically proven for most specific effects

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle with graduated dropper
• Carrier: Organic MCT oil
• Price: $129.99
• Shipping: Available to all addresses in Ouachita County, Arkansas

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram 510-thread cartridge
• Price: $49.99
• Compatibility: Works with any standard 510-thread battery
• Shipping: Available to all addresses in Ouachita County, Arkansas

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene — citrus-bright, mood-lifting
• Myrcene — earthy, relaxing
• Caryophyllene (β-caryophyllene) — pepper/spice, CB2 agonist
• Pinene — forest-fresh, clarity
• Linalool — floral, lavender, calming
• Humulene — earthy, woody, anti-inflammatory
• Terpinolene — piney, fruity, sparkling

ORDERING INFORMATION FOR OUACHITA COUNTY

Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Shipping to Arkansas: All orders ship within 1-2 business days. USPS Priority Mail delivers to Ouachita County in 2-3 business days. Tracking is provided for all orders.

Age requirement: 21+ only

Payment methods: All major credit cards accepted

Discreet packaging: Plain boxes with no cannabis branding

For questions about which product might be right for your specific situation in Ouachita County — whether you’re dealing with chronic pain from years of physical labor, chemotherapy side effects, PTSD, or sleep issues — call our team. We can’t give medical advice, but we can help you understand the evidence and make an informed decision.

Legal notice for Arkansas customers: This product contains hemp-derived cannabinoids with less than 0.3% delta-9 THC by dry weight, making it legal under the 2018 Farm Bill and Arkansas state law at the point of sale. THCa converts to delta-9 THC when heated. Customers accept responsibility for compliance with local laws regarding possession and use. Keep all products out of reach of children and pets. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Final thoughts for Ouachita County

We started this guide with Rick Simpson’s story because it’s the foundation of everything called “RSO” today. But we built OilWell’s formulas because Simpson’s original vision needed evolution — more precision, more safety, more options, and honest education about what the science actually shows.

Whether you’re in Camden or Bearden, Stephens or any of the rural communities that make Ouachita County special, you deserve access to cannabinoid medicine that reflects both the compassion of Simpson’s original mission and the scientific rigor of modern cannabinoid research. Bentley’s miracle wasn’t magic — it was chemistry applied with love. Colin’s recovery from benzo addiction wasn’t luck — it was precise formulation based on real pharmacology.

Our promise to Ouachita County is the same promise we’ve kept in Houston since 2019: we’ll tell you what we know, what we don’t know, and what the evidence actually says. We’ll ship you a product that’s been lab-tested for purity and potency. And if you can’t afford it, we’ll give you the recipe to make your own.

That’s not how most cannabis companies operate. But then again, most cannabis companies didn’t start with a paralyzed dog and a man who refused to give up on him.

Welcome to OilWell Cannabis. We’re glad you’re here, Ouachita County.